Making life science life changing
Shaping the future for people living with rare diseases and addressing global health challenges.
How we accelerate promising research
Scientific expertise
30 years of experience in antibody humanisation, diagnostics and biomarker development, and drug development.
Funding and investment
Funding promising science, including open funding calls and investment in early-stage ventures.
Intellectual property and tech transfer
Supporting licensing and collaborative development to accelerate the progress of research.
Interested in partnering with us?
We can work together to connect you with the right support for your project.
Our Translational Challenges
Each of our Translational Challenges targets a specific area or disease where research has great potential to deliver impact but lacks the translational infrastructure needed to bring discoveries to patients. We bring our science, advice and funding to these challenges, and work closely with partners to tap into their expertise and capabilities.
Motor Neuron Disease
Our vision is a world where motor neuron disease is preventable and treatable.
Chronic Respiratory Infection
Our vision is improved quality of life for those living with cystic fibrosis and bronchiectasis.
Global Health
Our vision is a world with affordable and accessible solutions to better understand, treat, and prevent infectious diseases.
Rare Disease
Our vision is an ecosystem working together to get discoveries and treatments to rare disease patients faster.
Childhood Cancer
Our vision is to drive life-changing innovations for children with cancer.
What’s happening at LifeArc
Our work in neurodegeneration
We’re working to improve prediction and diagnosis of neurodegenerative conditions.
2023 annual review
Read about the projects and initiatives that made 2023 at LifeArc such an eventful and successful year.
We’re hiring!
We’re looking for talented people to join the LifeArc team.
Latest news
-
LifeArc joins the REMEDi4ALL Consortium, a pioneering global platform shaping the future of drug repurposing
-
£1million partnership aims to develop new treatments for congenital muscular dystrophy
-
Tribune Therapeutics raises EUR 37 million for next-generation anti-fibrotic therapies